TABLE 1.

Probability of posaconazole serum AUC/MIC target attainment at respective MICs in 5,000 simulated patients

MIC (mg/liter)	Probability of posaconazole serum AUC/MIC target attainment (%) using:
	Suspension, 800 mg/day, EUCAST simulationsa	Suspension, 800 mg/day, current studyb	Tablets, 300 mg/dayc	Intravenous, 300 mg/dayd
0.015	99.9	99.0	99.9	99.9
0.03	96	97.0	99.9	99.9
0.06	68	83	99	99
0.125	15.3	64	95	97
0.25e	0.6	18	80	81
0.5	0	0	24	15
1.0	0	0	0	0
2.0	0	0	0	0

^aTarget AUC/MIC, >167; 200 mg 4 times daily; AUC, 10.6 mg · h/liter; coefficient of variation (CV), 83% (9, 27, 33).

^bTarget AUC/MIC, >100; 200 mg 4 times daily; AUC, 10.6 mg · h/liter; CV, 83% (27, 33).

^cTarget AUC/MIC, >100; 600 mg day 1, then 300 mg daily; AUC, 37.9 mg · h/liter; CV, 42% (27, 33).

^dTarget AUC/MIC, >100; 600 mg day 1, then 300 mg daily; AUC, 36.1 mg · h/liter; CV, 35% (27, 33).

^eCurrent EUCAST wild-type epidemiological cutoff for A. fumigatus.